Rapid Micro Biosystems, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. The company develops and sells its Growth Direct automated microbial quality-control platform, consumables, software and related services for pharmaceutical and other regulated manufacturing.
Financial performance
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $5.61 million | $5.04 million | Up 11.4% |
| Product revenue | $3.71 million | $3.32 million | Up 11.7% |
| Service revenue | $1.90 million | $1.71 million | Up 10.9% |
| Recurring revenue | $3.74 million; 66.7% of revenue | $3.25 million; 64.6% | Up 15.1% |
| Gross loss and margin | $1.52 million; (27.1)% | $1.79 million; (35.6)% | Margin improved about 8.5 percentage points |
| Operating loss | $14.27 million | $14.87 million | Improved $0.60 million |
| Net loss | $13.32 million | $13.89 million | Improved $0.57 million |
| Net loss per share | $0.31 | $0.32 | Improved $0.01 |
| Cash used in operations | $15.53 million | $16.69 million | Use decreased $1.16 million |
Product and service costs totaled $7.13 million, exceeding revenue; the company remains loss-making. Research and development expense rose 21.9% to $3.84 million, while sales and marketing expense fell 5.2% to $3.28 million and general and administrative expense fell 13.0% to $5.63 million. The G&A decline chiefly reflected lower bonus expense and legal and insurance costs.
Balance sheet and liquidity
- At March 31, cash and cash equivalents were $22.43 million and short-term investments were $57.10 million, totaling $79.54 million; restricted cash was an additional $0.28 million. The company stated these resources should fund operating and capital needs for at least 12 months after issuance of the statements.
- Current assets were $108.16 million versus current liabilities of $15.60 million. Total assets were $127.73 million, total liabilities $21.79 million, and stockholders’ equity $105.94 million.
- No conventional borrowings are reported on the balance sheet. Lease liabilities totaled approximately $7.07 million, including current and long-term amounts.
- Cash, cash equivalents and restricted cash decreased $1.85 million during the quarter. Investing activities provided $13.52 million, largely reflecting investment maturities; operating activities used $15.53 million.
- Accumulated deficit was $441.71 million. The company reported no material litigation and no declared or paid cash dividends.
Material changes and operating indicators
- Three systems were placed in both Q1 2024 and Q1 2023. Cumulative placements reached 144, compared with 128 a year earlier; cumulative validated systems reached 124, compared with 105.
- Product revenue growth was attributed mainly to higher consumables volume and average selling prices; system placements were unchanged. Service growth reflected more validation, installation and service-contract revenue.
- Two customers accounted for 33.7% of Q1 2024 revenue, down from 47.1% in the prior-year quarter. Two customers represented 55.4% of accounts receivable at quarter-end.
- Inventory was $20.42 million, up from $19.96 million at year-end. The company recorded an $85,000 provision for excess and obsolete inventory in the quarter.
Outlook, risks and unusual items
- No specific quarterly or full-year 2024 revenue, margin or earnings guidance is provided in the supplied filing text. Management expects continued operating losses and says revenue growth, customer adoption, validation timelines, cost control and gross-margin improvement are important to its prospects. It expects to continue investing in R&D, sales and marketing, manufacturing and support.
- Management reported improving gross margin, from (35.6)% to (27.1)%, while cautioning that system sales are variable and quarterly results can be affected by customer purchasing cycles, site readiness, validation and seasonality.
- The company received a Nasdaq notice on February 2, 2024 for falling below the $1.00 minimum bid price for 30 consecutive business days. The stated compliance deadline was July 31, 2024; management said a reverse stock split could be considered. Delisting was a potential risk if compliance was not regained.
- A camera supplier discontinued production of a component used in Growth Direct systems. The company said it had inventory it believed sufficient to meet demand while qualifying a replacement supplier, but noted that supply estimates and qualification timing could be wrong.
- Key risks include ongoing cash burn and possible future capital needs, adoption and commercial success of Growth Direct, customer and revenue concentration, competition, product reliability and regulatory-workflow expectations, supplier and inventory constraints, and inflation and interest-rate effects. Management identified no material change in market-risk exposure from its prior annual filing.
- Disclosure controls and procedures were assessed as effective at the reasonable-assurance level as of March 31, 2024; no material change in internal control over financial reporting was reported for the quarter.
Important facts for investors to verify
- Whether cash burn and available cash and investments continue to support management’s stated minimum 12-month funding outlook.
- Whether recurring revenue growth converts into improved gross margin and whether validated systems translate into sustained consumables and service use.
- Progress in qualifying a replacement camera supplier and maintaining product availability and reliability.
- Whether the company regained Nasdaq’s minimum bid-price compliance by the disclosed deadline and whether any listing action or reverse split followed.
- Customer concentration, inventory levels and any subsequent financing, guidance updates or material changes to the risk disclosures.